Blinken In China & 'Massive Downsizing' At Credit Suisse
Bloomberg Daybreak: Europe Edition
00:00
AstraZeneca Drafts Plan to Spin Off China Business and Mid Tensions
AstraZeneca has drawn up plans to spin off its business in China and possibly list in Hong Kong. Listing a separate unit could insulate the company politically from moves by China to really crack down on foreign companies. AstraZeneca is the largest overseas pharmaceutical company in China by sales. The drug maker generated $1.6 billion in the country in the first quarter.
Transcript
Play full episode
